Excellent response to primary treatment, final follow-up NED, tumor size ≤ 10 mm (compared with >10 mm and ≤20 mm), and classic cancer type (compared with other aggressive subtypes) were from 10% to 40% higher in patients without CHK2 expression than in those with CHK2 expression. This evidence concerns the gene CHEK2 and cancer.